{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T06:21:37Z","timestamp":1693722097529},"reference-count":39,"publisher":"FapUNIFESP (SciELO)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Hosp. Clin."],"published-print":{"date-parts":[[2002,2]]},"abstract":"<jats:p>PURPOSE: To determine the eradication rate of an ultra-short treatment schedule for Helicobacter pylori infection in a population with peptic ulcers, using omeprazole, secnidazole, and azithromycin in a once-daily dose for 3 days. METHODS: Thirty patients with peptic ulcer diagnosed by upper endoscopy and for Helicobacter pylori infection by rapid urease test and histologic examination received omeprazole 40 mg, secnidazole 1000 mg, and azithromycin 500 mg, administered once daily for 3 days. A follow-up exam was performed 12 weeks after the end of the treatment. Patients who were negative for Helicobacter pylori infection by rapid urease test and histologic examination were considered cured. RESULTS: Patients were predominantly female, and the mean age was 50 years. Duodenal peptic ulcer was found in 73% of the patients. Eradication was achieved in 9 of the 28 (32%) patients as determined from the follow-up endoscopic exam. The eradication rate by intention to treat was 30%. Side effects were present in 3% of the patients, and compliance to treatment was total. CONCLUSIONS: In spite of the low rate of side effects and good compliance, the eradication index was low. A possible drawback of this therapy is that it reduces the efficacy of macrolide and nitroimidazole compounds in subsequent treatments.<\/jats:p>","DOI":"10.1590\/s0041-87812002000100002","type":"journal-article","created":{"date-parts":[[2005,4,27]],"date-time":"2005-04-27T13:22:04Z","timestamp":1114608124000},"page":"9-14","source":"Crossref","is-referenced-by-count":5,"title":["Low efficacy of an ultra-short term, once-daily dose triple therapy with omeprazole, azithromycin, and secnidazole for Helicobacter pylori eradication in peptic ulcer"],"prefix":"10.1590","volume":"57","author":[{"given":"Fernando Marcuz","family":"Silva","sequence":"first","affiliation":[{"name":"University of S\u00e3o Paulo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaime Natan","family":"Eisig","sequence":"additional","affiliation":[{"name":"University of S\u00e3o Paulo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ethel Zimberg","family":"Chehter","sequence":"additional","affiliation":[{"name":"University of S\u00e3o Paulo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00falio Jovino da","family":"Silva","sequence":"additional","affiliation":[{"name":"University of S\u00e3o Paulo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio At\u00edlio","family":"Laudanna","sequence":"additional","affiliation":[{"name":"University of S\u00e3o Paulo"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1046\/j.1365-2036.1996.40182000.x","article-title":"Review article: clinic aspects of Helicobacter pylori eradication therapy in peptic ulcer disease","volume":"10","author":"PENSTON JG","year":"1996","journal-title":"Aliment Pharmacol Ther","ISSN":"http:\/\/id.crossref.org\/issn\/0269-2813","issn-type":"print"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3109\/00365529609094747","article-title":"Pooled analysis of anti-Helicobacter pylori treatment regimens","volume":"31","author":"UNGE P","year":"1996","journal-title":"Scand J Gastroentrol"},{"key":"ref3","first-page":"1545","article-title":"Drug therapy for Helicobacter pylori infection: Problems and pitfalls","volume":"85","author":"GLUPCZYNSKI I","year":"1990","journal-title":"Am J Gastroenterol","ISSN":"http:\/\/id.crossref.org\/issn\/0002-9270","issn-type":"print"},{"key":"ref4","first-page":"505","article-title":"Patient factors affecting Helicobacter pylori eradication with triple therapy","volume":"88","author":"CUTLER AF","year":"1993","journal-title":"Am J Gastroenterol","ISSN":"http:\/\/id.crossref.org\/issn\/0002-9270","issn-type":"print"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1046\/j.1365-2036.1998.00405.x","article-title":"Review article: one-week clarithromycin triple therapy regimens for eradication of Helicobacter pylori","volume":"12","author":"PIPKIN GA","year":"1998","journal-title":"Aliment Pharmacol Ther","ISSN":"http:\/\/id.crossref.org\/issn\/0269-2813","issn-type":"print"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1046\/j.1365-2036.1999.00530.x","article-title":"The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxicillin or metronidazole","volume":"13","author":"HUANG J","year":"1999","journal-title":"Aliment Pharmacol Ther","ISSN":"http:\/\/id.crossref.org\/issn\/0269-2813","issn-type":"print"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1046\/j.1365-2036.1999.00436.x","article-title":"Optimal duration of therapy combining ranitidine bismuth citrate with clarithromycin and metronidazole in the eradication of Helicobacter pylori infection","volume":"13","author":"SAVARINO V","year":"1999","journal-title":"Aliment Pharmacol Ther","ISSN":"http:\/\/id.crossref.org\/issn\/0269-2813","issn-type":"print"},{"key":"ref8","first-page":"1716","article-title":"Meta-analysis of the efficacy of antibiotic therapy in eradicating Helicobacter pylori","volume":"87","author":"CHIBA N","year":"1992","journal-title":"Am J Gastorenterol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.1994.03520010077036","article-title":"NATIONAL Institutes of Health Consensus Development Conference Statement: Helicobacter pylori in peptic ulcer disease","volume":"272","year":"1994","journal-title":"J A M A"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1136\/gut.41.1.8","article-title":"CURRENT European concepts in the management of Helicobacter pylori infection: The Maastricht Consensus Report. European Helicobacter pylori Study Group","volume":"41","year":"1997","journal-title":"Gut","ISSN":"http:\/\/id.crossref.org\/issn\/0017-5749","issn-type":"print"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1440-1746.1998.tb00537.x","article-title":"Report of the 1997 ASIA Pacific Consensus Conference on the management of Helicobacter pylori infection","volume":"13","author":"LAM SK","year":"1998","journal-title":"J Gastroenterol Hepatol","ISSN":"http:\/\/id.crossref.org\/issn\/0815-9319","issn-type":"print"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1155\/1999\/180751","article-title":"Canadian Helicobacter pylori Consensus Conference update: infections in adults","volume":"13","author":"HUNT RH","year":"1999","journal-title":"Can J Gastroenterol","ISSN":"http:\/\/id.crossref.org\/issn\/0835-7900","issn-type":"print"},{"key":"ref13","first-page":"1629","article-title":"Helicobacter pylori eradication after 7 days triple therapy with PPI bid + tinidazole 500mg bid+ clarithromycin 250mg bid: Risk factors related to treatment failure","volume":"92","author":"ZATERKA S","year":"1997","journal-title":"Am J Gastroenterol","ISSN":"http:\/\/id.crossref.org\/issn\/0002-9270","issn-type":"print"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/j.1572-0241.1998.216_a.x","article-title":"Weekend therapy for the treatment of Helicobacter pylori infection","volume":"93","author":"TUCCI A","year":"1998","journal-title":"Am J Gastroenterol","ISSN":"http:\/\/id.crossref.org\/issn\/0002-9270","issn-type":"print"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1046\/j.1365-2036.1999.00436.x","article-title":"Optimal duration of therapy combining ranitidine bismuth citrate with clarithromycin and metronidazole in the eradication of Helicobacter pylori infection","volume":"13","author":"SAVARINO V","year":"1999","journal-title":"Aliment Pharmacol Ther","ISSN":"http:\/\/id.crossref.org\/issn\/0269-2813","issn-type":"print"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1046\/j.1365-2036.2000.00664.x","article-title":"Five-day regimens containing Ranitidine Bismuth Citrate plus high-dose clarithromycin and either amoxycillin or tinidazole for Helicobacter pylori infection","volume":"14","author":"CAMMAROTA G","year":"2000","journal-title":"Aliment Pharmacol Ther","ISSN":"http:\/\/id.crossref.org\/issn\/0269-2813","issn-type":"print"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/j.1572-0241.1998.00390.x","article-title":"A four-day low dose triple therapy regimen for the treatment of Helicobacter pylori infection","volume":"93","author":"TREVISANI L","year":"1998","journal-title":"Am J Gastroenterol","ISSN":"http:\/\/id.crossref.org\/issn\/0002-9270","issn-type":"print"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1046\/j.1523-5378.2000.00007.x","article-title":"Four-day, quadruple therapy with amoxicillin, clarithromycin, tinidazole and omeprazole to cure Helicobacter pylori infection: a pilot study","volume":"5","author":"CALVET X","year":"2000","journal-title":"Helicobacter","ISSN":"http:\/\/id.crossref.org\/issn\/1083-4389","issn-type":"print"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"621","DOI":"10.2165\/00003495-199651040-00007","article-title":"Secnidazole: A review of its antimicrobial activity, pharmacokinetic properties and therapeutic use in the management of protozoal infections and bacterial vaginosis","volume":"51","author":"GILLIS JC","year":"1996","journal-title":"Drugs","ISSN":"http:\/\/id.crossref.org\/issn\/0012-6667","issn-type":"print"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/37.suppl_C.1","article-title":"Azithromycin: - review of key chemical, pharmacokinetic and microbiological features","volume":"37","author":"LODE H","year":"1996","journal-title":"J Antimicrob Chemoter"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"483","DOI":"10.2165\/00003495-199651030-00013","article-title":"Azithromycin: A review of its pharmacological properties and use as 3-day therapy in respiratory tract infections","volume":"51","author":"DUNN CJ","year":"1996","journal-title":"Drugs","ISSN":"http:\/\/id.crossref.org\/issn\/0012-6667","issn-type":"print"},{"key":"ref22","first-page":"322","article-title":"Metronidazole-resistant Helicobacter pylori in a developing country","volume":"88","author":"QUEIROZ DMM","year":"1993","journal-title":"Am J Gastroenterol","ISSN":"http:\/\/id.crossref.org\/issn\/0002-9270","issn-type":"print"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1046\/j.1523-5378.2000.00011.x","article-title":"Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxicillin, tetracycline, and furazolidone in Brazil","volume":"5","author":"MENDONCA S","year":"2000","journal-title":"Helicobacter","ISSN":"http:\/\/id.crossref.org\/issn\/1083-4389","issn-type":"print"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1046\/j.1365-2036.1999.00653.x","article-title":"Omeprazole, clarithromycin and furazolidone for the eradication of Helicobacter pylori in patients with duodenal ulcer","volume":"13","author":"DANI R","year":"1999","journal-title":"Aliment Pharmacol Ther","ISSN":"http:\/\/id.crossref.org\/issn\/0269-2813","issn-type":"print"},{"key":"ref25","first-page":"162","article-title":"Five-day and ten-day triple therapy (amoxicillin, furazolidone and metronidazole) in the treatment of duodenal ulcer","volume":"51","author":"ZATERKA S","year":"1996","journal-title":"Rev Hosp Clin Fac Med S Paulo"},{"key":"ref26","first-page":"81","article-title":"Helicobacter pylori: erradica\u00e7\u00e3o em curto prazo com o esquema Belo Horizonte modificado","volume":"13","author":"FRANCO JMM","year":"1994","journal-title":"G E D"},{"key":"ref27","first-page":"A118","article-title":"H. pylori eradication: High efficacy week treatment with clarithromycin 500mg bid, amoxicillin 1,0g bid plus lansoprazole 30 mg bid in S\u00e3o Paulo - Brazil","volume":"94","author":"CHEHTER EZ","year":"1999","journal-title":"Am J Gastroenterolol"},{"key":"ref28","first-page":"264","article-title":"Azithromycin for the cure of Helicobacter pylori infection","volume":"91","author":"DI MARIO F","year":"1996","journal-title":"Am J Gastroenterol","ISSN":"http:\/\/id.crossref.org\/issn\/0002-9270","issn-type":"print"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/00042737-199701000-00012","article-title":"Short-term low-dose triple therapy with azithromycin, metronidazole and lansoprazole appears highly effective for the eradication of Helicobacter pylori","volume":"9","author":"CASELLI M","year":"1997","journal-title":"Eur J Gastroenterol Hepatol","ISSN":"http:\/\/id.crossref.org\/issn\/0954-691X","issn-type":"print"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1046\/j.1365-2036.1996.d01-533.x","article-title":"Helicobacter pylori eradication using one-week low-dose lansoprazole plus amoxycillin and either clarithromycin or azithromycin","volume":"10","author":"CAMMAROTA G","year":"1996","journal-title":"Aliment Pharmacol Ther","ISSN":"http:\/\/id.crossref.org\/issn\/0269-2813","issn-type":"print"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1046\/j.1365-2036.2000.00662.x","article-title":"Pantoprazole, amoxicillin and either azithromycin or clarithromycin for eradication of Helicobacter pylori in duodenal ulcer","volume":"14","author":"VCEV A","year":"2000","journal-title":"Aliment Pharmacol Ther","ISSN":"http:\/\/id.crossref.org\/issn\/0269-2813","issn-type":"print"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1046\/j.1365-2036.1998.00422.x","article-title":"Low-dose versus high-dose azithromycin triple therapy for Helicobacter pylori infection","volume":"12","author":"CHEY WB","year":"1998","journal-title":"Aliment Pharmacol Ther","ISSN":"http:\/\/id.crossref.org\/issn\/0269-2813","issn-type":"print"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"A94","DOI":"10.1016\/S0016-5085(98)80379-X","article-title":"- Azithromycin, furazolidone and omeprazole: a promising low-dose, low cost, short-term, anti-H. pylori triple therapy","volume":"14","author":"COELHO LGV","year":"1998","journal-title":"Gastroenterology","ISSN":"http:\/\/id.crossref.org\/issn\/0016-5085","issn-type":"print"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.3109\/00365529409094890","article-title":"Omeprazole plus amoxicillin for cure of Helicobacter pylori infection: Factors influencing the treatment success","volume":"29","author":"LABENS J","year":"1994","journal-title":"Scand J Gastroenterol","ISSN":"http:\/\/id.crossref.org\/issn\/0036-5521","issn-type":"print"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1046\/j.1365-2036.1996.95267000.x","article-title":"Helicobacter pylori eradication in clinical practice: one-week low-dose triple therapy is preferable to classical bismuth based triple therapy","volume":"10","author":"GODDARD AF","year":"1996","journal-title":"Aliment Pharmacol Ther","ISSN":"http:\/\/id.crossref.org\/issn\/0269-2813","issn-type":"print"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0016-5085(99)70119-8","article-title":"The MACH2 Study: Role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies","volume":"116","author":"LIND T","year":"1999","journal-title":"Gastroenterology","ISSN":"http:\/\/id.crossref.org\/issn\/0016-5085","issn-type":"print"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1128\/AAC.31.12.1939","article-title":"Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms","volume":"31","author":"RETSEMA J","year":"1987","journal-title":"Antimicrob Agents Chemother","ISSN":"http:\/\/id.crossref.org\/issn\/0066-4804","issn-type":"print"},{"issue":"suppl 196","key":"ref38","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3109\/00365529309098341","article-title":"Compliance, adverse events and antibiotic resistance in Helicobacter pylori treatment","volume":"28","author":"MALFERTHEINER P","year":"1993","journal-title":"Scand J Gastroenterol","ISSN":"http:\/\/id.crossref.org\/issn\/0036-5521","issn-type":"print"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0016-5085(99)70145-9","article-title":"Helicobacter pylori, acid and omeprazole revisited: bacterial eradication and rebound hypersecretion","volume":"116","author":"KUIPERS EJ","year":"1999","journal-title":"Gastroenterology","ISSN":"http:\/\/id.crossref.org\/issn\/0016-5085","issn-type":"print"}],"container-title":["Revista do Hospital das Cl\u00ednicas"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/rhc\/v57n1\/a02v57n1.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,5,24]],"date-time":"2017-05-24T22:13:06Z","timestamp":1495663986000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0041-87812002000100002&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,2]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2002,2]]}},"alternative-id":["S0041-87812002000100002"],"URL":"https:\/\/doi.org\/10.1590\/s0041-87812002000100002","relation":{},"ISSN":["0041-8781"],"issn-type":[{"value":"0041-8781","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,2]]}}}